Natixis Advisors
CHRS icon

Natixis Advisors’s Coherus Oncology CHRS Stock Holding History

Natixis Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,460
Closed -$251K – 1463
2022
Q1 		$251K Buy
19,460
+2,687
+16% +$34.2K ﹤0.01% 1397
2021
Q4 		$268K Buy
16,773
+1,933
+13% +$33.8K ﹤0.01% 1325
2021
Q3 		$238K Buy
+14,840
New +$218K ﹤0.01% 1294
2021
Q1 		– Sell
-163,934
Closed -$2.85M – 1263
2020
Q4 		$2.85M Buy
+163,934
New +$2.92M 0.02% 740

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Natixis Advisors's CHRS Position: Q2 2022 in Review

Natixis Advisors sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 19,460 shares — an estimated $251K sold.

Natixis Advisors first reported a position in CHRS in Q4 2020 and held it in 4 quarters. The position peaked at $2.85M in Q4 2020. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

  • Natixis Advisors reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
  • Natixis Advisors sold 19,460 Coherus Oncology shares in Q2 2022, an estimated $251K.
  • Natixis Advisors first reported a position in Coherus Oncology in Q4 2020 and held it in 4 quarters.
  • Natixis Advisors's Coherus Oncology position peaked at $2.85M in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Natixis Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.